| Entry |
|
|---|
| Name |
Epalrestat (JP18/INN);
Kinedak (TN) |
|---|
| Formula |
C15H13NO3S2
|
|---|
| Exact mass |
319.0337
|
|---|
| Mol weight |
319.3986
|
|---|
| Structure |
|
|---|
| Class |
Antidiabetic agent
DG01882 Aldose reductase inhibitor
|
|---|
| Remark |
| Therapeutic category: | 3999 |
|
|---|
| Efficacy |
Hypoglycemic, Aldose reductase inhibitor |
|---|
| Comment |
Use for treatment of accumulation of Sorbitol [CPD: C00794] harm cells.
|
|---|
| Target |
|
|---|
| Pathway |
| hsa00051 | Fructose and mannose metabolism |
|
|---|
| Interaction |
|
|---|
| Brite |
Therapeutic category of drugs in Japan [BR:br08301]
3 Agents affecting metabolism
39 Other agents affecting metabolism
399 Miscellaneous
3999 Others
D01688 Epalrestat (JP18/INN)
Drug groups [BR:br08330]
Antidiabetic agent
DG01882 Aldose reductase inhibitor
D01688 Epalrestat
Target-based classification of drugs [BR:br08310]
Enzymes
Oxidoreductases (EC1)
Dehydrogenases
AKR1B1
D01688 Epalrestat (JP18/INN) <JP>
Drugs listed in the Japanese Pharmacopoeia [BR:br08311]
Chemicals
D01688 Epalrestat
D01688 Epalrestat tablets
|
|---|
| Other DBs |
|
|---|
| KCF data |
ATOM 21
1 C8x C 15.2303 -16.8093
2 C8x C 15.2303 -18.2105
3 C8x C 16.4476 -18.9075
4 C8x C 17.6576 -18.2105
5 C8y C 17.6576 -16.8093
6 C8x C 16.4476 -16.1051
7 C2b C 18.8726 -16.1061
8 C2c C 20.0864 -16.8111
9 C2b C 21.3014 -16.1078
10 C1a C 20.0854 -18.2122
11 C2y C 22.3935 -16.8924
12 C2y C 24.2355 -18.2245
13 N1y N 24.6694 -16.8924
14 C5x C 23.5315 -16.0629
15 S2x S 22.8344 -18.2245
16 O5x O 23.5313 -14.6618
17 S0 S 25.0537 -19.3604
18 C1b C 25.8761 -16.1756
19 C6a C 27.0979 -16.8667
20 O6a O 28.3048 -16.1497
21 O6a O 27.1129 -18.2678
BOND 22
1 4 5 1
2 9 11 2
3 5 6 2
4 6 1 1
5 5 7 1
6 12 13 1
7 13 14 1
8 14 11 1
9 11 15 1
10 15 12 1
11 1 2 2
12 14 16 2
13 7 8 2
14 12 17 2
15 2 3 1
16 13 18 1
17 8 9 1
18 18 19 1
19 3 4 2
20 19 20 2
21 8 10 1
22 19 21 1
|
|---|
